The Lodi plant – Acquired by the Group in 2001, over the years the Lodi plant was subjected to a complete and radical renovation of the existing production areas, which resulted in the creation of a very modern production unit where high-tech lines have been set up for the development of innovative procedures.
The plant stands on a total area of 12,000 m2 and includes: 12 production departments, the warehouse and the raw material sampling areas, the dispensing department for the preparation of work orders, the Research and Development labs, the Quality Control, Microbiology and Chemistry labs and the Regulatory, Quality Assurance, Production, Engineering and Maintenance offices. The pharmaceutical production area and the raw materials warehouse occupy 5,500 m2, while the nutritional production area, with its dedicated warehouse, occupies a space of 1,000 m2. A total of 224 employees work in the plant.
The plant produces injectables – both through aseptic processing and terminal sterilization – in traditional vials and in pre-filled syringes, preparations for topical use (creams, gels, solutions) in BoV (Bag-on-Valve) and soft capsules (soft gel). The production lines of the plant are in the forefront in terms of technology and eco-environmental sustainability. The significant investments made in the modernisation of the industrial plants and in the process lines allowed to achieve high standards of efficiency.
The pharmaceutical products of the Lodi plant serve the IBSA Group and directly supply several markets, including – in addition to Italy – Switzerland, England, Hungary, Slovakia, Czech Republic, Poland, Greece, Spain, the Scandinavian countries, Russia, Egypt, Turkey, the United Arab Emirates, US, Brazil and Korea.